Enterprise Profile

Revenue in millions of dollars

BD Biosciences is one of the world’s leading businesses focused on bringing innovative research and clinical tools to life scientists and clinicians.

Principal product lines include fluorescence activated cell sorters and analyzers; cell imaging systems; monoclonal antibodies and kits; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; and diagnostic assays.
     BD Biosciences customers are involved in basic research, drug and vaccine discovery and development, clinical trials, and diagnostic testing and disease management. This diverse customer base includes academic and government institutions, pharmaceutical and biotech companies, and the clinical segment.
     Cell analysis is the focus of the Immunocytometry Systems and Pharmingen units, both of which have experienced solid growth driven by the successful introduction of new platforms and reagents. With the launches of several flow cytometry platforms and associated sample preparation and automation systems over the past few years, the business is well-positioned in each major customer segment addressed. The 2004 acquisition of Atto Bioscience provided a cell imaging platform, enabling BD Biosciences to cover the continuum from cell analysis to cell sorting to cell imaging.
     In the research products sector, BD Biosciences maintains a leadership position by offering extremely capable instruments and a broad line of monoclonal antibody-based reagents. In addition to serving basic research customers, BD Biosciences is a key provider to the pharmaceutical industry, where improving the productivity of the drug discovery process is a leading imperative. To achieve that goal, researchers are increasingly using cell-based assays, an area that plays to BD Biosciences’ core business capabilities and strategic focus. BD Biosciences’ new imaging instruments enable researchers to better understand biological processes through real-time imaging of live cell processes. BD Biosciences’ growing line of drug metabolism assays help make pharmaceutical companies’ drug discovery processes more productive by providing in vitro tests that screen out non-viable drug candidates early, thus increasing the ultimate likelihood of clinical trial success. In addition, through its Discovery Labware unit, BD Biosciences provides a broad array of products for the laboratory, including products for tissue culture, fluid handling and cultureware.
     In the clinical products sector, BD Biosciences’ platforms are considered to be the “gold standard” for CD4 testing, used for HIV/AIDS therapy monitoring and in leukemia/lymphoma typing. BD Biosciences looks forward to maintaining and growing its leading position in clinical flow cytometry and plans to develop new platforms and assays in response to unmet and growing needs in the clinical segment.

The BD Pathway 435 is an affordable, compact bioimager that rapidly acquires high-resolution cell images to support high-content cell analysis for pharmaceutical, biotechnology, academic and government research customers. BD Phosflow is a highly innovative flow cytometry-based technology, enabling phosphorylation state analysis of multiple proteins at single cell levels that enhances cell signaling network analysis and efficacy testing in drug discovery. The BD Falcon 96-well Imaging Plate is specially designed for automated imaging systems. Its superior flatness and proven performance on a wide range of imaging platforms make it the plate of choice for high-content screening assays. The new BD FACSCanto II system offers a range of turnkey in vitro diagnostics applications, as well as the flexibility and cutting-edge performance required for complex life science and clinical research.